[version 1; peer review: not peer reviewed]
This message is a response from the ISCB in light of the recent the
The recent editorial by Drs. Longo and Drazen in the
ISCB acknowledges that the additional comment on the editorial
Data produced with public money should be public for the benefit of science and society
Restrictions to the use of public data hamper science and slow progress
Open data is the best way to combat fraud and misinterpretations
Current large data collections proceed from many sources, are continually accumulated, and require a variety of analytical approaches. Data generation and data analysis overlap in time and are continually updated with new data sets produced by new techniques and new analysis methodologies. Furthermore, in many cases current science functions in consortia in which scientists collaborate toward common goals while preserving their own scientific objectives. Dividing scientists into data providers and data analysts is simplistic and gives a misleading impression of the actual state of biological and biomedical science.
ISCB very much supports collaboration between disciplines, including experimental and clinical disciplines as well as bioinformatics, as the best way forward to address complex biological problems. But this collaboration cannot be based on imposed restrictions to data access and cannot be contained in professional silos. (The use of expressions such as “research parasites” clearly does not help.)
In this spirit, ISCB recently launched the ISCB Community Journal (ISCB Comm J), which is published on the F1000Research publishing platform. F1000Research and ISCB Comm J have a robust data sharing policy. All primary research articles include the submission of the data underlying the results, together with details of any software used to process results.
Many bio-communities have made significant progress by endorsing open data policies and, gratefully, public funding agencies have connected to the spirit that they are distributing taxpayers’ money to science and that, therefore, the data that are generated in the course belong to the public. It is, perhaps, natural that some areas of biomedical research are slow in adopting these policies. History and the confidential nature of the relevant data are surely some of the reasons. However, in our opinion, data hegemony is another reason and this has to be overcome. The sooner these barriers to progress are removed the sooner patients will benefit from the current flourishing of biomedical research.